Literature DB >> 23686135

Danger signalling during cancer cell death: origins, plasticity and regulation.

A D Garg1, S Martin, J Golab, P Agostinis.   

Abstract

Accumulating data indicates that following anti-cancer treatments, cancer cell death can be perceived as immunogenic or tolerogenic by the immune system. The former is made possible due to the ability of certain anti-cancer modalities to induce immunogenic cell death (ICD) that is associated with the emission of damage-associated molecular patterns (DAMPs), which assist in unlocking a sequence of events leading to the development of anti-tumour immunity. In response to ICD inducers, activation of endoplasmic reticulum (ER) stress has been identified to be indispensable to confer the immunogenic character of cancer cell death, due to its ability to coordinate the danger signalling pathways responsible for the trafficking of vital DAMPs and subsequent anti-cancer immune responses. However, in recent times, certain processes apart from ER stress have emerged (e.g., autophagy and possibly viral response-like signature), which have the ability to influence danger signalling. In this review, we discuss the molecular nature, emerging plasticity in the danger signalling mechanisms and immunological impact of known DAMPs in the context of immunogenic cancer cell death. We also discuss key effector mechanisms modulating the interface between dying cancer cells and the immune cells, which we believe are crucial for the therapeutic relevance of ICD in the context of human cancers, and also discuss the influence of experimental conditions and animal models on these.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686135      PMCID: PMC3858605          DOI: 10.1038/cdd.2013.48

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  126 in total

1.  Cutting edge: selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection.

Authors:  G C Pien; A R Satoskar; K Takeda; S Akira; C A Biron
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

Review 2.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

3.  Human TH1 and TH2 subsets: doubt no more.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1991-08

Review 4.  Oncolytic viruses for induction of anti-tumor immunity.

Authors:  Alex W Tong; Neil Senzer; Vincenzo Cerullo; Nancy Smyth Templeton; Akseli Hemminki; John Nemunaitis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

6.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Authors:  Mélanie Bruchard; Grégoire Mignot; Valentin Derangère; Fanny Chalmin; Angélique Chevriaux; Frédérique Végran; Wilfrid Boireau; Benoit Simon; Bernhard Ryffel; Jean Louis Connat; Jean Kanellopoulos; François Martin; Cédric Rébé; Lionel Apetoh; François Ghiringhelli
Journal:  Nat Med       Date:  2012-12-02       Impact factor: 53.440

Review 7.  Exosome: from internal vesicle of the multivesicular body to intercellular signaling device.

Authors:  K Denzer; M J Kleijmeer; H F Heijnen; W Stoorvogel; H J Geuze
Journal:  J Cell Sci       Date:  2000-10       Impact factor: 5.285

8.  Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.

Authors:  Mara Cirone; Livia Di Renzo; Lavinia Vittoria Lotti; Valeria Conte; Pankaj Trivedi; Roberta Santarelli; Roberta Gonnella; Luigi Frati; Alberto Faggioni
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

9.  In vitro studies on erythrosine-based photodynamic therapy of malignant and pre-malignant oral epithelial cells.

Authors:  Abhishek D Garg; Muthiah Bose; Mohammed I Ahmed; William A Bonass; Simon R Wood
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

10.  High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.

Authors:  U Andersson; H Wang; K Palmblad; A C Aveberger; O Bloom; H Erlandsson-Harris; A Janson; R Kokkola; M Zhang; H Yang; K J Tracey
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  90 in total

1.  Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis.

Authors:  Abhishek D Garg; Dirk De Ruysscher; Patrizia Agostinis
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 2.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 3.  Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Authors:  Jonathan Pol; Erika Vacchelli; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

4.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

5.  Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.

Authors:  Abhishek D Garg; Lien Vandenberk; Matthias Van Woensel; Jochen Belmans; Marco Schaaf; Louis Boon; Steven De Vleeschouwer; Patrizia Agostinis
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

6.  Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance.

Authors:  Sheng-Yen Lin; Sung-Yuan Hsieh; Yi-Ting Fan; Wen-Chi Wei; Pei-Wen Hsiao; Dai-Hua Tsai; Tzong-Shoon Wu; Ning-Sun Yang
Journal:  Autophagy       Date:  2017-12-31       Impact factor: 16.016

Review 7.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

Review 8.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.

Authors:  Nicole S Klee; Cameron G McCarthy; Patricia Martinez-Quinones; R Clinton Webb
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-09-15

9.  Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.

Authors:  Daniel Hao Lin; Arijit Biswas; Mahesh Choolani; Chui-Yee Fong; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

10.  Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.

Authors:  Joshua P Landreneau; Michael R Shurin; Marianna V Agassandian; Anton A Keskinov; Yang Ma; Galina V Shurin
Journal:  Cancer Microenviron       Date:  2013-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.